BCL2 and plasma cell myeloma: Looking forward, a first-in-human phase 1 study of novel BCL-2 inhibitor lisaftoclax is underway in multiple myeloma and other hematologic malignancies with doses up to 1200 mg/day thus far being well-tolerated (NCT03537482) (81).